Cargando…

Two-Year US Pharmacovigilance Report on Brodalumab

INTRODUCTION: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the U...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lebwohl, Mark, Leonardi, Craig, Wu, Jashin J., Armstrong, April, Rawnsley, Nicole, Merchant, Mohammed, Alexander, Binu, Jacobson, Abby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859129/ https://www.ncbi.nlm.nih.gov/pubmed/33337520 http://dx.doi.org/10.1007/s13555-020-00472-x

Ejemplares similares

Three‐year U.S. pharmacovigilance report of brodalumab
por: Lebwohl, Mark, et al.
Publicado: (2021)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
por: Menter, Alan, et al.
Publicado: (2020)

Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
por: Gottlieb, Alice, et al.
Publicado: (2020)

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
por: Lebwohl, Mark G., et al.
Publicado: (2019)

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
por: Menter, Alan, et al.
Publicado: (2022)

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
por: Lebwohl, Mark G., et al.
Publicado: (2015)

Brodalumab in psoriasis: evidence to date and clinical potential
por: Foulkes, Amy C, et al.
Publicado: (2019)

Rapid resolution of pyoderma gangrenosum with brodalumab therapy
por: Tee, Michael W., et al.
Publicado: (2020)

Brodalumab in the treatment of psoriatic arthritis – the latest reports
por: Banaszczyk, Katarzyna
Publicado: (2021)

Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)
por: Papp, K., et al.
Publicado: (2020)

Clinical potential of brodalumab in the management of psoriasis: the evidence to date
por: Sandoval, Laura F, et al.
Publicado: (2015)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab
por: Megna, Matteo, et al.
Publicado: (2022)

Protocol for the safety of brodalumab regarding psychiatric comorbidities in patients with psoriasis
por: Pikou, O., et al.
Publicado: (2022)

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
por: Pinter, Andreas, et al.
Publicado: (2019)

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study
por: Reilev, Mette, et al.
Publicado: (2023)

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
por: Coimbra, Susana, et al.
Publicado: (2014)

Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report
por: Yeung, Jensen, et al.
Publicado: (2020)

SAPHO Syndrome Complicated by Lesions of the Central Nervous System Successfully Treated with Brodalumab
por: Funabiki, Masahide, et al.
Publicado: (2023)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
por: REICH, Kristian, et al.
Publicado: (2022)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review
por: Cannizzaro, Maria Vittoria, et al.
Publicado: (2023)

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
por: Roman, Michael, et al.
Publicado: (2017)

Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study
por: Yamaguchi, Yukie, et al.
Publicado: (2020)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
por: Wu, Jashin J., et al.
Publicado: (2020)

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
por: Wu, Jashin J., et al.
Publicado: (2020)

Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review
por: Merola, Joseph F., et al.
Publicado: (2022)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis
por: Elgaard, Cathrine Dawn Büttner, et al.
Publicado: (2023)

Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities
por: Kugener, Veronique F., et al.
Publicado: (2021)

Pharmacovigilance
por: Griffin, J. P.
Publicado: (1992)

Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology
por: Baldo, Paolo, et al.
Publicado: (2018)

Pharmacovigilance system in Saudi Arabia
por: Alshammari, Thamir M., et al.
Publicado: (2017)

Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors
por: Kokolakis, Georgios, et al.
Publicado: (2021)

Effectiveness of Long-Term Treatment with Brodalumab on Anxiety or Depressive Symptoms in Japanese Patients with Psoriasis: The ProLOGUE Study
por: Ohata, Chika, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2gkfs0p798219v2m2unhrbf2vu